JBI-589 is a non-covalent, orally bioavailable, isoform-selective inhibitor of PAD4 (Protein Arginine Deiminase 4). It has been shown to reduce CXCR2 expression and block neutrophil chemotaxis. This compound can decrease primary tumors and metastases, and also enhance the anti-tumor effect of checkpoint inhibitors. JBI-589 is suitable for use in cancer research.
- Reduces CXCR2 expression and blocks neutrophil chemotaxis
- Decreases primary tumors and metastases
- Enhances anti-tumor effect of checkpoint inhibitors
- Suitable for cancer research
- Inhibits citrullination of histone H3 in Phorbol 12-myristate 13-acetate-induced mouse neutrophils
- Significantly inhibits growth of primary tumors in mouse models